OBD vs. OKYO, SAR, AOR, OPTI, AREC, IMM, POLB, RLM, NSCI, and SNG
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include OKYO Pharma (OKYO), Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Arecor Therapeutics (AREC), ImmuPharma (IMM), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs.
Oxford BioDynamics (LON:OBD) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.
Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.
OKYO Pharma has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.
Oxford BioDynamics received 97 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 63.64% of users gave OKYO Pharma an outperform vote while only 60.47% of users gave Oxford BioDynamics an outperform vote.
OKYO Pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,800.32%. Oxford BioDynamics' return on equity of -289.38% beat OKYO Pharma's return on equity.
44.3% of Oxford BioDynamics shares are held by institutional investors. 16.8% of Oxford BioDynamics shares are held by insiders. Comparatively, 31.9% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Oxford BioDynamics beats OKYO Pharma on 7 of the 12 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 5/22/2025 by MarketBeat.com Staff
